metyrapone and Adrenal Cortex Cancer studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Research Excerpts

Excerpt	Relevance	Reference
"To analyse the clinical and biochemical effects of metyrapone in the treatment of Cushing's syndrome."	7.68	Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. ( Besser, GM; Grossman, AB; Howlett, TA; Perry, L; Rees, LH; Trainer, PJ; Verhelst, JA; Wass, JA, 1991)
"Aldosterone excretion was high, normal, or low in each of the three types of Cushing's syndrome."	5.26	Deoxycorticosterone and aldosterone excretion in Cushing's syndrome. ( Cassar, J; Joplin, GF; Kelly, WF; Loizou, S; Mashiter, K, 1980)
"To analyse the clinical and biochemical effects of metyrapone in the treatment of Cushing's syndrome."	3.68	Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. ( Besser, GM; Grossman, AB; Howlett, TA; Perry, L; Rees, LH; Trainer, PJ; Verhelst, JA; Wass, JA, 1991)
"Subnormal plasma 11-deoxycortisol (compound S) responses to metyrapone were found in patients with adrenal insufficiency or with Cushing syndrome caused by adrenal tumors and in those receiving long-term glucocorticoid or diphenylhydantoin sodium therapy."	3.65	Single-dose metyrapone test: review of a four-year experience. ( Jubiz, W; Meikle, AW; Spiger, M; Tylor, FH; West, CD, 1975)
"Cushing's syndrome is a complex endocrine condition with potential serious complications if untreated or inadequately treated."	2.45	Drugs in the medical treatment of Cushing's syndrome. ( Schteingart, DE, 2009)
"Metyrapone inhibition was associated with a concomitant increase in the formation of androgens (androstenedione and testosterone) from pregnenolone."	1.31	Biosynthesis and metabolism of steroid hormones by human adrenal carcinomas. ( Brown, JW; Fishman, LM, 2000)
"Aminoglutethimide was examined only for effects on CYP11A activity and was shown to inhibit pregnenolone formation (20 microM: 61 +/- 4% of control)."	1.31	Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. ( Johansson, MK; Lund, BO; Sanderson, JT, 2002)
"Aldosterone excretion was high, normal, or low in each of the three types of Cushing's syndrome."	1.26	Deoxycorticosterone and aldosterone excretion in Cushing's syndrome. ( Cassar, J; Joplin, GF; Kelly, WF; Loizou, S; Mashiter, K, 1980)

Research

Studies (24)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Number of Participants With Adverse Events

Timeframe	Studies, this research(%)	All Research%
pre-1990	10 (41.67)	18.7374
1990's	5 (20.83)	18.2507
2000's	6 (25.00)	29.6817
2010's	3 (12.50)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Claps, M	1
Cerri, S	1
Grisanti, S	1
Lazzari, B	1
Ferrari, V	1
Roca, E	1
Perotti, P	1
Terzolo, M	1
Sigala, S	1
Berruti, A	1
Delivanis, DA	1
Athimulam, S	1
Bancos, I	1
Syed, AA	1
Demssi, YN	1
Schteingart, DE	1
Lubin, V	1
Gautier, JF	1
Antoine, JM	1
Beressi, JP	1
Vexiau, P	1
Satoh, F	1
Ito, S	1
Plager, JE	1
Bertagna, C	1
Orth, DN	1
Sindler, BH	1
Griffing, GT	1
Melby, JC	1
Cassar, J	2
Loizou, S	2
Kelly, WF	2
Mashiter, K	2
Joplin, GF	2
Miller, JW	1
Crapo, L	1
Tamura, H	1
Sugihara, H	1
Minami, S	1
Emoto, N	1
Shibasaki, T	1
Shuto, Y	1
Shimizu, K	1
Gomi, Y	1
Sasano, H	1
Wakabayashi, I	1
Fassnacht, M	2
Beuschlein, F	2
Vay, S	1
Mora, P	1
Allolio, B	2
Reincke, M	2
Brown, JW	1
Fishman, LM	2
Hahner, S	1
Klink, A	1
Johansson, MK	1
Sanderson, JT	1
Lund, BO	1
Delaney, JP	1
Solomkin, JS	1
Jacobson, ME	1
Doe, RP	1
Barnes, AJ	1
White, M	1
Welbourn, RB	1
deAsis, DN	1
Samaan, NA	1
Spiger, M	1
Jubiz, W	1
Meikle, AW	1
West, CD	1
Tylor, FH	1
Carballeira, A	1
Jacobi, JD	1
Kato, S	1
Masunaga, R	1
Kawabe, T	1
Nagasaka, A	1
Miyamoto, T	1
Itoh, M	1
Nakai, A	1
Iwase, K	1
Tsujimura, T	1
Ohtani, S	1
Verhelst, JA	1
Trainer, PJ	1
Howlett, TA	1
Perry, L	1
Rees, LH	1
Grossman, AB	1
Wass, JA	1
Besser, GM	1
Wand, GS	1
Ney, RL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer[NCT01255137]	Phase 2	13 participants (Actual)	Interventional	2010-09-30	Completed
An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome[NCT00569582]	Phase 3	50 participants (Actual)	Interventional	2007-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse events module. (NCT01255137)
Timeframe: 3/2/11 - 8/2/12

Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC)

Intervention	Participants (Number)
Adrenal Cortex Neoplasms	13

Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10mm. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameter. Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: the appearance of one or more new lesions is also considered progression). Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking s reference the smallest sum diameters while on study. (NCT01255137)
Timeframe: 2 years

Decrease in Diastolic Blood Pressure.

Intervention	Participants (Number)
	Complete Response	Partial Response	Progression	Stable Disease
Adrenal Cortex Neoplasms	0	0	13	0

Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit. (NCT00569582)
Timeframe: Baseline to Week 24

Improvement in Diabetes and/or Glucose Intolerance.

Intervention	participants (Number)
Mifepristone	8

Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance. (NCT00569582)
Timeframe: Baseline to Week 24

Article	Year
Drugs in the medical treatment of Cushing's syndrome. Expert opinion on emerging drugs, 2009, Volume: 14, Issue:4 Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Antiparkinson Agents; Cabergoline; Cushing Sy	2009
[Cushing's syndrome during pregnancy]. Presse medicale (Paris, France : 1983), 2002, Nov-09, Volume: 31, Issue:36 Topics: Adrenal Cortex Neoplasms; Adult; Anti-Inflammatory Agents; Antimetabolites; Cushing Syndrome; Dexame	2002
[Adrenocortical adenoma]. Nihon rinsho. Japanese journal of clinical medicine, 2006, May-28, Volume: Suppl 1 Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Aldosterone; Androgens; Biomarkers;	2006
The medical treatment of Cushing's syndrome. Endocrine reviews, 1993, Volume: 14, Issue:4 Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Aminoglutethimide; Animals; Bromocriptine; Cushing Syndrom	1993
New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line. European journal of clinical investigation, 2000, Volume: 30 Suppl 3 Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Aminoglutethimide; Cell Division; Cholesterol Side-Chain C	2000
Disorders of the hypothalamic-pituitary-adrenal axis. Clinics in endocrinology and metabolism, 1985, Volume: 14, Issue:1 Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenal Hyperplasia, Congenital; Adrenal Insuffic	1985

Article	Year
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma. Endocrine, 2018, Volume: 61, Issue:1 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; An	2018
Modern Management of Mild Autonomous Cortisol Secretion. Clinical pharmacology and therapeutics, 2019, Volume: 106, Issue:6 Topics: 14-alpha Demethylase Inhibitors; Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenalectomy; Adr	2019
Medical image. Adrenocortical carcinoma presenting with hirsutism: an uncommon cause of a common complaint. The New Zealand medical journal, 2014, Mar-07, Volume: 127, Issue:1390 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antimetabolites; Diagnosis, Differential; Fatal	2014
Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. International advances in surgical oncology, 1984, Volume: 7 Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocorticotropi	1984
Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). The American journal of medicine, 1981, Volume: 71, Issue:5 Topics: Adenoma; Adolescent; Adrenal Cortex Function Tests; Adrenal Cortex Neoplasms; Adrenocorticotropic Ho	1981
The superiority of the metyrapone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome. The American journal of medicine, 1983, Volume: 74, Issue:4 Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Cortodoxone; Cushing Syndrome; Dexamethasone; Dia	1983
Deoxycorticosterone and aldosterone excretion in Cushing's syndrome. Metabolism: clinical and experimental, 1980, Volume: 29, Issue:2 Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adrenal Glands; Adult; Aged; Aldosterone; Carcinoma;	1980
Cushing's syndrome due to bilateral adrenocortical adenomas with different pathological features. Internal medicine (Tokyo, Japan), 1997, Volume: 36, Issue:11 Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adrenocorticotropic Hormone; Codon;	1997
Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line. The Journal of endocrinology, 1998, Volume: 159, Issue:1 Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Analysis of V	1998
Biosynthesis and metabolism of steroid hormones by human adrenal carcinomas. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2000, Volume: 33, Issue:10 Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Aldosterone; Buclade	2000
Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicology in vitro : an international journal published in association with BIBRA, 2002, Volume: 16, Issue:2 Topics: Adrenal Cortex Neoplasms; Aminoglutethimide; Carcinoma; Chromatography, High Pressure Liquid; Colfor	2002
Surgical management of Cushing's syndrome. Surgery, 1978, Volume: 84, Issue:4 Topics: Adenoma; Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocorticotropic Ho	1978
Cushing's syndrome due to adrenocortical carcinoma - a comphrensive clinical and biochemical study of patients treated by surgery and chemotherapy. Acta endocrinologica, 1979, Volume: 91, Issue:2 Topics: 17-Ketosteroids; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Aldosterone; Carcinoma; Cort	1979
Feminizing adrenocortical carcinoma with Cushing's syndrome and pseudohyperparathyroidism. Archives of internal medicine, 1978, Volume: 138, Issue:2 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adult	1978
Single-dose metyrapone test: review of a four-year experience. Archives of internal medicine, 1975, Volume: 135, Issue:5 Topics: Adenoma, Chromophobe; Adolescent; Adrenal Cortex Neoplasms; Adrenal Gland Diseases; Adrenal Glands;	1975
Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies. The Journal of clinical endocrinology and metabolism, 1976, Volume: 42, Issue:4 Topics: Adenoma; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenal Glands; Adrenoco	1976
Cushing's syndrome induced by hypersecretion of cortisol from only one of bilateral adrenocortical tumors. Metabolism: clinical and experimental, 1992, Volume: 41, Issue:3 Topics: Adenoma; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adult; Cosyntropin; Cushing Syndrome; De	1992
Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clinical endocrinology, 1991, Volume: 35, Issue:2 Topics: ACTH Syndrome, Ectopic; Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone;	1991

metyrapone and Adrenal Cortex Cancer